Clinical trial · no report yet · Phase 2
NCT03646123
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
- NCT03646123 ↗
- Terminated
- Seagen Inc.
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin; doxorubicin; vinblastine; dacarbazine; G-CSF; nivolumab
- Arms
- Part A: A+AVD · Experimental
- Part B: AN+AD · Experimental
- Part C: AN+AD · Experimental
- Enrollment
- 255
- Primary outcomes
- Febrile Neutropenia (FN) Rate (Part A)
- Complete Response (CR) Rate at EOT (Parts B and C)
- Sponsor
- Seagen Inc. with Bristol-Myers Squibb
- Start
- Jan 28, 2019
- Primary completion
- Nov 7, 2022
- Results posted
- Yes
- Registry record
- NCT03646123 · updated Aug 28, 2025
Publications
linked from the registry- Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary. Future Oncol. 2026 Jul;22(17):2027-2040. doi: 10.1080/14796694.2026.2693614. Epub 2026 Jul 6. PubMed 42405616
- Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ. Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma. Blood. 2026 Apr 9;147(15):1713-1722. doi: 10.1182/blood.2025030190. PubMed 41460964
- Lee HJ, Ramchandren R, Friedman J, Melear J, Flinn IW, Burke JM, Linhares Y, Gonzales P, Peterson M, Raval M, Chintapatla R, Feldman TA, Yimer H, Islas-Ohlmayer M, Patel A, Metheny L, Dean A, Rana V, Gandhi MD, Renshaw J, Ho L, Fanale MA, Guo W, Yasenchak CA. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025 Jan 16;145(3):290-299. doi: 10.1182/blood.2024024681. PubMed 39622165